Korsana Biosciences, Inc.
KRSA - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$18.3M
Close$
$4.09
86.4% downside
Current Fair Value
86.4% downsideOvervalued by 86.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $18.30 Million |
|---|---|
| Enterprise Value | $16.91 Million |
| Earnings per Share | $-7.63 |
| Beta | 1.73 |
| Outstanding Shares | 607,286 |
Return
| Return on Equity | -131.85% |
|---|---|
| Return on Assets | -96.78% |
| Return on Invested Capital | -133.24% |
Valuation & Multiples
| P/E Ratio | -2.5 |
|---|---|
| PEG | -0.57 |
| Price to Sales | 10.05 |
| Price to Book Ratio | 3.77 |
| Enterprise Value to Revenue | 8.9 |
| Enterprise Value to EBIT | -2.5 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-3.45
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.85
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Cyclerion Therapeutics Inc
1 employees
CEO: Jonathan Violin
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules ...